As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
In short
The commercial pact with Eli Lilly prompted an immediate positive market reaction for Hims & Hers shares. Under the agreed terms, the telehealth company committed to ending its compounding of GLP-1 medications like Zepbound. This agreement establishes a direct relationship with the major drugmaker while phasing out alternative formulation practices.
Key points
- Hims & Hers has officially established a direct GLP-1 partnership with pharmaceutical mak…: Hims & Hers has officially established a direct GLP-1 partnership with pharmaceutical maker Eli Lilly.
- The company will abandon compounding practices for weight-loss medications like Zepbound…: The company will abandon compounding practices for weight-loss medications like Zepbound under the deal.
- Investor enthusiasm over the new pharmaceutical arrangement drove a rapid surge in the co…: Investor enthusiasm over the new pharmaceutical arrangement drove a rapid surge in the company's share price.